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Introduction {#path4591-sec-0001}
============

The acid‐producing oxyntic mucosa of the stomach consists of glands that are divided into pit, isthmus, neck and base zones, based on the presence of characteristic cell types. To supply the constant turnover of the distinct mature cell lineages, the glands have multipotent stem cells that self‐renew and give rise to progenitor cells that differentiate further [1](#path4591-bib-0001){ref-type="ref"}, [2](#path4591-bib-0002){ref-type="ref"}, [3](#path4591-bib-0003){ref-type="ref"}. These oxyntic stem/progenitor cells have been described morphologically and are believed to reside in the isthmus zone, which has been shown to be the predominant location of immature cells and cellular proliferation [2](#path4591-bib-0002){ref-type="ref"}, [4](#path4591-bib-0004){ref-type="ref"}, [5](#path4591-bib-0005){ref-type="ref"}. Many putative markers for gastric stem cells have been proposed, although none have proved to completely fulfil the requirements of adult stem cells in the mature oxyntic mucosa [6](#path4591-bib-0006){ref-type="ref"}, [7](#path4591-bib-0007){ref-type="ref"}, [8](#path4591-bib-0008){ref-type="ref"}, [9](#path4591-bib-0009){ref-type="ref"}. LGR5 is a promising stem cell marker in all gastric mucosal areas during embryonic development and in adult antrum, but apparently not in adult corpus [10](#path4591-bib-0010){ref-type="ref"}, [11](#path4591-bib-0011){ref-type="ref"}. However, a recent report shows *Lgr5* expression in a small subset of fully differentiated chief cells located at the oxyntic gland base. These cells also express the new stem cell marker *Troy* and can serve as quiescent 'reserve' stem cells activated by tissue damage. *Troy* is not expressed in the proliferating oxyntic isthmus zone and does not seem to mark the main physiological renewing stem cells, which are yet to be identified specifically [9](#path4591-bib-0009){ref-type="ref"}. This indicates more plasticity in the oxyntic mucosa than was previously recognized. In general, much less is known about the gastric oxyntic stem/progenitor cells, which seem to differ from the more studied intestinal and antral stem cells [6](#path4591-bib-0006){ref-type="ref"}, [7](#path4591-bib-0007){ref-type="ref"}, [8](#path4591-bib-0008){ref-type="ref"}.

A predominant concept is that resident adult stem/progenitor cells can accumulate mutations, undergo transformation and thereby become cancer‐initiating and cancer stem cells. These are defined as having the ability to self‐renew and to provide all the heterogeneous cells that comprise a tumour, thus being responsible for its maintenance and growth [12](#path4591-bib-0012){ref-type="ref"}, [13](#path4591-bib-0013){ref-type="ref"}. Despite the progress in unravelling the molecular carcinogenesis of gastric adenocarcinomas (GAs), clinical outcome is little improved and the disease still remains a worldwide health problem. The role of cancer stem cells is not fully understood [7](#path4591-bib-0007){ref-type="ref"}, [8](#path4591-bib-0008){ref-type="ref"}. Increased knowledge about the gastric stem cell niche is important to improve understanding of normal cellular homeostasis and to elucidate the underpinning mechanisms involved in common diseases of the stomach. Due to the lack of specific biomarkers and methods to isolate stem/progenitor cells, eg for gene expression analysis, these cells have been difficult to study. Laser microdissection (LM) enables rapid and precise sampling of defined morphological areas from heterogeneous tissue sections. This is a valuable approach for specific high‐throughput analysis and identification of candidate molecular markers, which have an important place in understanding cell position, type and relations in the dynamic renewal of gastric glands. Such knowledge is also required to recognize markers that would be suitable for further studies, eg by clonal lineage tracing.

Thus, we have developed a method using serial section‐navigated LM to isolate cells from the proliferative isthmus zone of rat gastric oxyntic mucosa for genome‐wide gene expression analysis. We introduce ASPM \[Asp (abnormal spindle) homologue, microcephaly‐associated (*Drosophila*)\] as a novel gastric cell marker, possibly for the oxyntic stem/progenitor cells, and are the first to investigate ASPM in association with the stem cell‐related E2F transcription factor 1 (E2F1) in normal and malignant gastric tissues.

Materials and methods {#path4591-sec-0002}
=====================

Gastric cell lines, animal and human tissues {#path4591-sec-0003}
--------------------------------------------

The study was approved by the Norwegian National Animal Research Authority and the animals were handled according to guidelines described previously [14](#path4591-bib-0014){ref-type="ref"}. Oxyntic mucosal biopsies were taken from the greater curvature and either immediately frozen in liquid nitrogen for the preparation of frozen sections or fixed in formalin for immunohistochemistry (IHC). The human material used was extracted RNA and formalin fixed, paraffin‐embedded (FFPE) biopsies from GAs, adjacent non‐tumour mucosa and matched normal mucosa. The patients gave written informed consent and the study was approved by the Regional Medical Research Ethics Committee of Central Norway (Approval No. 018--02). The human gastric adenocarcinoma cell lines AGS \[American Type Culture Collection (ATCC), Rockville, MD, USA\], MKN‐45 (gift from Queens Medical Centre, University Hospital, Nottingham, UK) and KATO‐III (ATCC) were grown under standard conditions (see supplementary material, Supplementary materials and methods). Whole‐cell extracts were prepared and protein concentrations measured, as described previously [15](#path4591-bib-0015){ref-type="ref"}.

Laser microdissection and RNA isolation {#path4591-sec-0004}
---------------------------------------

Biopsies from rat oxyntic mucosa (*n =* 6) were mounted in Tissue‐Tek OCT (Sakura, Alpena an den Rijn, The Netherlands) and from each biopsy a 5 µm guiding section was cut, followed by three 16 µm sections which were mounted on membrane slides \[Molecular Machines and Industries (MMI), Zurich, Switzerland\]. The guiding section was stained for the proliferation marker Ki67 to identify the isthmus zone and placed in the MMI CellCut Plus instrument (with Olympus IX71 inverted microscope) together with the sequential unstained sections from which the tissue was harvested. The isthmus zone was located using the software\'s serial section function (CellTools, v. 4.0.9) that allowed the operator to transfer information about the cutting area from one stained guiding section to unstained serial sections. RNA was extracted from the microdissected tissues using RNAqueous Micro Kit (Life Technologies, Grand Island, NY, USA); the first incubation was performed with the tubes upside down, to ensure lysis of the harvested tissue adherent to the MMI cap. RNA integrity was measured as a RIN score using the Bioanalyser system (Agilent Technologies, Santa Clara, CA, USA) (see supplementary material, Supplementary materials and methods).

Genome‐wide gene expression analysis {#path4591-sec-0005}
------------------------------------

The cRNA was prepared with Ambion\'s Illumina^®^ TotalPrep™‐96 RNA Amplification Kit (Life Technologies), using all extracted total RNA from the laser‐microdissected samples as input material. For each sample, the biotin‐labelled cRNA concentrations were checked (NanoDrop, Thermo Fisher Scientific, Wilmington, DE, USA) and adjusted to 150 ng/µl before hybridization to RatRef‐12 Expression BeadChip (Illumina, San Diego, CA, USA). Only probes abiding to the Illumina detection *p* value of 0.01 in at least one sample were included in further analyses, using the limma (v. 3.12.1) Bioconductor package [16](#path4591-bib-0016){ref-type="ref"} for paired *t*‐tests. A FDR adjusted *p* value \< 0.05 was taken as significant. Differentially expressed genes, with expression above the Illumina detection limit in ≥ 5 samples from the isthmus zone and expression above background in ≤ 1 sample from the remaining oxyntic mucosa, were defined as genes unique for the isthmus zone. The microarray data are available from the ArrayExpress Repository [17](#path4591-bib-0017){ref-type="ref"} (Accession No. E‐MTAB‐2542). Canonical pathways, gene‐disease association and transcriptional networks associations were determined by MetaCore^TM^ [18](#path4591-bib-0018){ref-type="ref"} and enrichment analysis, with a *p* \< 0.05 threshold for the data inputs (see supplementary material, Supplementary materials and methods). Expression profile analyses of *ASPM* and *E2F1* mRNA in multiple human gastric cancer datasets were performed using the Oncomine database ([www.oncomine.org](http://www.oncomine.org)) and an in‐house gene expression dataset, where RNA isolation and microarray analysis followed standard protocols using 300 ng total RNA/sample on Human HT‐12 Expression Bead Chips (Illumina; see Accession No. E‐MTAB‐1338).

Immunohistochemistry and in situ hybridization {#path4591-sec-0006}
----------------------------------------------

The frozen guiding sections (5 µm) were fixed in precooled ethanol and endogenous peroxidases quenched prior to incubation with a Ki67 antibody for 2 h at room temperature (RT). Standard pretreatments such as permeabilization, quenching of endogenous peroxidases and antigen retrieval of FFPE sections (4 µm) were followed by incubation with the primary antibodies for 1--2 h at RT, or overnight at 4 °C. All single‐stained sections were prepared using the rabbit/mouse EnVision‐HRP/DAB^+^ kit (Dako, Glostrup, Denmark) and counterstaining with haematoxylin. For double‐stained sections, primary antibodies were incubated simultaneously and visualized following 1 h of incubation at RT with fluorescent secondary antibodies or Lectin GS‐II (Life Technologies) and counterstaining with DAPI. Tyramide Signal Amplification (TSA kits, Life Technologies) was used for ASPM and E2F1 in combination with other antibodies. *In situ* hybridization (ISH) for *ASPM* mRNA was performed using an RNAscope 2.0 HD Reagent Kit (Brown) for FFPE tissue (310035; Advanced Cell Diagnostics (ACD), Hayward, CA, USA) and probeset (427881, ACD) according to the manufacturer\'s instructions, except for increased boiling time (Pretreat 2; see supplementary material, Supplementary materials and methods).

Western blot and immunocytochemistry {#path4591-sec-0007}
------------------------------------

Proteins (60 µg/well) were separated on 3--8% NuPage Novex Tris/acetate gels (Invitrogen) and electroblotted onto Immobilon PVDF membranes (Millipore). The membranes were blocked and binding of the primary antibodies (ASPM, E2F1 and β‐actin) and HRP‐conjugated or fluorescent secondary antibodies were visualized using the Odyssey Fc imaging system (LI‐COR Biosciences, Lincoln, NE, USA). For immunocytochemistry, cells were grown in eight‐well Lab‐Tek™ Chambered Coverglass (NUNC, Thermo Scientific, Rockford, IL, USA), fixed with paraformaldehyde, permeabilized (Triton‐X) and blocked with bovine serum albumin (BSA). The cells were incubated overnight at 4 °C with the primary antibodies, reblocked and incubated for 1 h with fluorescent secondary antibodies. DNA was stained with DAPI (see supplementary material, Supplementary materials and methods).

Histomorphometry, statistical analysis and imaging {#path4591-sec-0008}
--------------------------------------------------

Immunoreactivity in GAs and normal human mucosa was evaluated by mean index value, by multiplying staining intensity (weak = 1, moderate = 2, strong = 3) and percentage of immunoreactive cells (\<10% = 1, 10--50% = 2, \> 50% = 3) from five randomly selected areas (500 × 500 µm) in each sample. Immunofluorescent staining was evaluated using an Olympus IX71 inverted microscope with a digital monochrome XM10 camera and Cell^P^ software (Olympus Co., Tokyo, Japan), or a Leica SP8 inverted microscope (Leica Microsystems, Mannheim, Germany) equipped with an HC plan‐apochromat 63×/1.4 CS2 oil‐immersion objective, with light laser and hybrid (HyD) detectors. Statistically significant differences (ANOVA with Bonferroni\'s multiple comparison test and two‐sided Fisher\'s exact test) and correlation (Pearson) were analysed using Prism 5 (GraphPad Software, San Diego, CA, USA).

Results {#path4591-sec-0009}
=======

Genome‐wide analysis shows a distinct gene expression profile of the oxyntic proliferative isthmus zone compared to the remaining mucosa {#path4591-sec-0010}
----------------------------------------------------------------------------------------------------------------------------------------

Serial section‐navigated LM provided enough RNA of sufficient quality (mean RIN 8.0; see supplementary material, Supplementary results) to compare the gene expression profiles in the isthmus zone to the remaining mucosa (Figure 1Ai--iii). Initial interpretation of the data was done using principal component analysis (PCA); this showed that the principal variation was within each animal, with the gene expression profiles of the isthmus zone and the remaining mucosa constituting two distinctly different tissue zones (Figure [1](#path4591-fig-0001){ref-type="fig"}B). Of the 1131 differentially expressed transcripts, 599 were more and 532 were less abundant in the isthmus zone compared to the remaining mucosa (see supplementary material, Table S1).

![Gene expression analysis of the rat oxyntic proliferative isthmus zone sampled by laser microdissection. (A) Schematic illustration of the architectural organization of the gastric oxyntic gland, showing positions of major cell types in the different regions -- pit, isthmus, neck and base. Stem and progenitor cells in the isthmus region are highlighted. Frozen sections of rat oxyntic mucosa showing: (i) immunostaining for the proliferation marker Ki67 (brown), used as a guide for the isthmus zone during laser microdissection, and representative examples of unstained frozen sections after laser microdissection of (ii) the isthmus zone and (iii) the remaining mucosa used for RNA extraction and genome‐wide gene expression analysis. (B) Plot from principal component analysis (PCA) visualizing variation between the expression profiles of the 12 different samples; each point represents one sample from the microdissected isthmus zone (Aii) (blue ![](PATH-237-447-g006.jpg "image")) and the remaining mucosa (Aiii) (red ![](PATH-237-447-g007.jpg "image")); the axis indicates the percentage of total variance explained in each component. (C) \'MetaCore transcriptional regulation\' algorithm with default settings was used to generate the top‐scored E2F1‐centred transcriptional network for the genes (n = 51) uniquely expressed in the microdissected isthmus zone (Aii); The transcriptional regulation is indicated as known (green arrows) or possible (grey arrows); other symbols are as specified in the figure. Scale bars = 100 µm](PATH-237-447-g001){#path4591-fig-0001}

To search for molecular processes that might characterize the two tissue zones, differentially expressed genes were subjected to enrichment analysis. For the genes (513 identified IDs) over‐expressed in the isthmus zone compared to the remaining mucosa, we found that the top‐scoring canonical pathways and networks were related to cell cycle phases and protein translation (Table [1](#path4591-tbl-0001){ref-type="table-wrap"}). In contrast, the genes (447 identified IDs) that were under‐expressed in the isthmus zone were significantly enriched in pathways and networks related to growth‐factor regulation (eg the stomach hormone gastrin), differentiation and unfolded protein response (UPR)/ER‐stress (Table [1](#path4591-tbl-0001){ref-type="table-wrap"}). Many of these under‐expressed genes (see supplementary material, Table S1) are known gastrin‐responsive genes and are expressed by mature cells located at the base of oxyntic glands [14](#path4591-bib-0014){ref-type="ref"}, [19](#path4591-bib-0019){ref-type="ref"}, [20](#path4591-bib-0020){ref-type="ref"}.

###### 

Canonical pathways and networks most significantly associated with genes expressed at higher or lower levels in the oxyntic proliferative isthmus zone compared to the remaining mucosa

  **Enrichment by MetaCore™**                                                                                         ***p***     **Network objects from active data** [a](#path4591-note-0004){ref-type="fn"} ^,^ [b](#path4591-note-0005){ref-type="fn"}
  ------------------------------------------------------------------------------------------------------------------- ----------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Genes over‐expressed in the isthmus zone**                                                                                    
  *Pathway maps*                                                                                                                  
  Cell cycle_Sister chromatid cohesion                                                                                1.22E‐08    PCNA, DNA polymerase sigma, Rad21, DCC1, RFC3, Separase, Histone H1, CDK1 (p34)
  Cell cycle_Role of APC in cell cycle regulation                                                                     3.33E‐07    BUB1, Geminin, Cyclin A, PLK1, Aurora‐B, Kid, CDC20, CDK1 (p34)
  Cell cycle_Spindle assembly and chromosome separation                                                               4.316E‐07   TPX2, CSE1L, KNSL1, Aurora‐B, Kid, CDC20, Separase, CDK1 (p34)
  *Process networks*                                                                                                              
  Cell cycle_S‐phase                                                                                                  2.12E‐12    BUB1, β‐Tubulin, SPBC25, TPX2, CSE1L, Cyclin A, PARP‐2, PLK1, Actin, KNSL1, Aurora‐B, HP1γ, ASPM, Kid, CDCA1, HP1, CDC20, Rad21, Separase, MKLP1, Histone H1, CDK1 (p34)
  Cell cycle_Mitosis                                                                                                  4.05E‐07    BUB1, β‐Tubulin, SPBC25, TPX2, CSE1L, Cyclin A, PARP‐2, PLK1, Actin, KNSL1, Aurora‐B, HP1γ, ASPM, Kid, CDCA1, HP1, CDC20, Rad21, Separase, MKLP1, Histone H1, CDK1 (p34)
  Translation_Translation initiation                                                                                  3.70E‐07    rpL23a, RPL39, RPL19, RPL26, RPS5, RPL3, RPL29, eIF5A, RPS8, PABPC1, RPS15, RPS21, RPL23, RPL27, eIF3S5, RPL35, RPS2, eIF3S3, RPS7, RPLP0, RPS25
  **Genes under‐expressed in the isthmus zone**                                                                                   
  *Pathway maps*                                                                                                                  
  Cell cycle_Sister chromatid cohesion protein folding and maturation_Angiotensin system maturation\\rodent version   1.84E‐07    Angiotensin II, Angiotensin IV, Angiotensin I, Angiotensin III, Angiotensin (2--10), CD13[\*](#path4591-note-0006){ref-type="fn"}, Angiotensin (1--7), Angiotensinogen[\*\*](#path4591-note-0007){ref-type="fn"}, Angiotensin (1--9)
  Development_Gastrin in differentiation of the gastric mucosa                                                        5.09E‐06    VMAT2, HDC, PKC‐β, ICRF, IP3 receptor, PKC, cPKC (conventional)
  Translation_Regulation of EIF4F activity                                                                            4.92E‐05    p38 MAPK, 4E‐BP1, PDK (PDPK1), p70 S6 kinase2, eIF4E, PAK1, EGF
  *Process networks*                                                                                                              
  Protein folding_Response to unfolded proteins                                                                       1.06E‐08    HSP90, ATF‐4, Endoplasmin, CHIP, GRP78, HSP70, UFD2, Calnexin, Glutaredoxin, PDI, HERP, XBP1, SELS
  Cell cycle_G~1~--S growth factor regulation                                                                         6.33E‐06    STAT3, PDGF‐A, IGF‐2, G‐protein α‐i family, Inhibin‐α, NDPK‐A, IKKβ, TGFβ3, LTBP3, Tob1, PKCβ, FGFR1, PKC, EGF, TGFβ, ActRIIB, cPKC (conventional)
  Development_Regulation of angiogenesis                                                                              9.85E‐06    IRAK1/2, STAT3, Angiotensin II, PDGF‐A, G‐protein α‐i family, Angiotensin III, PDK (PDPK1), Calnexin, IRAK1, BTG1, PLCδ, CD13, IP3 receptor, PKC, PAK1, PLCδ, Clusterin, ITGA7

The objects are generated by MetaCore tools [18](#path4591-bib-0018){ref-type="ref"} based on 513 uploaded gene IDs.

The objects are generated by MetaCore tools based on 447 uploaded gene IDs (see supplementary material, Table S1).

CD13 alias, *Anpep* (ILMN_1350090).

*Agt* (ILMN_1361016).

In accordance with earlier reports [4](#path4591-bib-0004){ref-type="ref"}, [6](#path4591-bib-0006){ref-type="ref"}, [7](#path4591-bib-0007){ref-type="ref"}, [8](#path4591-bib-0008){ref-type="ref"}, [10](#path4591-bib-0010){ref-type="ref"}, [21](#path4591-bib-0021){ref-type="ref"}, the mRNA levels of eg *Prom1*, *Tff2*, *Dclk1*, *Pcna*, *Muc6* and *Adam17* were higher in the oxyntic isthmus zone, while others were not differentially expressed (*Sox2*) or not detected (*Lgr5*, *Msh‐1*, *Sox9* or *CD44*) (see supplementary material, Table S1). Further analysis of ADAM17 by IHC showed strong expression in possibly preparietal cells in the isthmus zone, which agrees with our gene expression data but not with earlier reported localization [22](#path4591-bib-0022){ref-type="ref"}, [23](#path4591-bib-0023){ref-type="ref"} (see supplementary material, Supplementary results, Figure S1). Overall, we find that our gene expression data corroborate previous results (see supplementary material, Table S2). This validates our experimental set‐up using serial section‐navigated LM and shows a distinctly different expression profile of the proliferative isthmus zone compared to the remaining oxyntic mucosa.

Genes expressed in the oxyntic proliferative isthmus zone are associated with stem cell transcriptional networks and stomach neoplasia {#path4591-sec-0011}
--------------------------------------------------------------------------------------------------------------------------------------

To further characterize the gene expression signature of cells in the oxyntic proliferative isthmus zone, the genes over‐expressed in this zone compared to the remaining mucosa were analysed for transcriptional networks. We identified sub‐networks with a centre of transcription factors including c‐MYC, OCT‐3/4, E2F1, NANOG and KLF4. These are important in maintaining pluripotency [24](#path4591-bib-0024){ref-type="ref"}, [25](#path4591-bib-0025){ref-type="ref"} and self‐renewal of pluripotent stem cells [26](#path4591-bib-0026){ref-type="ref"}, [27](#path4591-bib-0027){ref-type="ref"} and were predicted to be regulators of several (*n =* 165, 84, 83, 71 and 57, respectively) of the 513 over‐expressed genes (data not shown). In addition, when the genes uniquely expressed (*n =* 51) in the isthmus zone (ie below detection limit in the remaining mucosa) (see supplementary material, Table S3) were analysed separately, the top scored transcriptional network was centred on the transcription factor E2F1 (Table [2](#path4591-tbl-0002){ref-type="table-wrap"}, Figure [1](#path4591-fig-0001){ref-type="fig"}C). Some of the 12 unique genes in this network (*N‐Myc*, *Rpa2*, *Mklp1*, *Stathmin*, *Pole2* and *Cyclin A*) are known to be transcriptionally regulated by E2F1 [28](#path4591-bib-0028){ref-type="ref"}, [29](#path4591-bib-0029){ref-type="ref"}, [30](#path4591-bib-0030){ref-type="ref"} (Figure [1](#path4591-fig-0001){ref-type="fig"}C, green arrows), while others (*Ace1*, *Ube2t*, *γ‐Adductin*, *Cdca1*, *Tim* and *Aspm*) have been identified as possible E2F1 target genes by ChIP--chip analysis [27](#path4591-bib-0027){ref-type="ref"}, [31](#path4591-bib-0031){ref-type="ref"}, [32](#path4591-bib-0032){ref-type="ref"}, [33](#path4591-bib-0033){ref-type="ref"}, [34](#path4591-bib-0034){ref-type="ref"} (Figure [1](#path4591-fig-0001){ref-type="fig"}C, grey arrows). A gene--disease association analysis indicated that the genes over‐expressed in the isthmus zone compared to the remaining mucosa were significantly associated with neoplasm in the gastrointestinal system. Interestingly, the transcription factor E2F1 was predicted to regulate many of the genes associated with stomach neoplasm, including all 12 unique genes (Figure [1](#path4591-fig-0001){ref-type="fig"}C) (see supplementary material, Supplementary materials and methods, Table S4). Thus, from our genome‐wide data we can deduce that the genes expressed in the proliferative isthmus zone of oxyntic mucosa are associated with stem cell transcriptional networks and stomach neoplasm.

###### 

Top scored transcriptional networks for genes unique for the oxyntic proliferative isthmus zone[a](#path4591-note-0008){ref-type="fn"}

  **Key network objects**   ***p***    **Network objects from active data** [b](#path4591-note-0009){ref-type="fn"}
  ------------------------- ---------- ---------------------------------------------------------------------------------------------
  E2F1                      2.07e‐39   γ‐Adductin, Cyclin A2, CDCA1, POLE2, n‐Myc, TIM, RPA2, ASPM, MKLP1, ACE1, UBE2T, Stathmin
  CREB1                     4.77e‐36   Cyclin A2, Stathmin, RPA2, RHAMM, MARCKS, C19orf6, CDA1, STAT5B, LTBP1, PFTAIRE‐1, KIAA1712
  c‐Myc                     2.21e‐29   BUB1, ACE1, Stathmin, MKLP1, PFTAIRE‐1, Cyclin A, C6orf108, N‐Myc, RHAMM
  E2F4                      4.46e‐26   UBE2T, ASPM, Stathmin, N‐Myc, CDCA1, MKLP1, RHAMM, Cyclin A2
  c‐Jun                     1.57e‐19   LTBP1, Cyclin A2, STAT5B, MARCKS, RHAMM, THAS
  ZNF143                    1.57e‐19   FANCB, C19orf6, Stathmin, BUB1, MKLP1, Cyclin A2
  P53                       1.57e‐19   THAS, Cyclin A2, Stathmin, DCC1, RHAMM, N‐Myc

The 51 genes were below detection threshold in the remaining mucosa, as described in Materials and methods; see also supplementary material, Table S3.

Analysis in MetaCore [18](#path4591-bib-0018){ref-type="ref"} using the \'Transcriptional regulation algorithm\' with default settings resulted in sub‐networks with a centre of various transcription factors. The seven top scored networks (by the number of pathways \> 5) are listed.

ASPM is expressed in scattered epithelial cells in the oxyntic proliferative isthmus zone {#path4591-sec-0012}
-----------------------------------------------------------------------------------------

Among the possible E2F1 target genes (Figure [1](#path4591-fig-0001){ref-type="fig"}C), *Aspm* seemed particularly interesting to investigate further, as it is associated with stem cells in other tissues [35](#path4591-bib-0035){ref-type="ref"}, [36](#path4591-bib-0036){ref-type="ref"}, [37](#path4591-bib-0037){ref-type="ref"}, [38](#path4591-bib-0038){ref-type="ref"}, [39](#path4591-bib-0039){ref-type="ref"}, [40](#path4591-bib-0040){ref-type="ref"}, [41](#path4591-bib-0041){ref-type="ref"} and is a suggested target gene for c‐MYC [27](#path4591-bib-0027){ref-type="ref"}, [42](#path4591-bib-0042){ref-type="ref"} and KLF4 [27](#path4591-bib-0027){ref-type="ref"}. In addition, E2F1 and ASPM share a functional association with cell cycle regulation [26](#path4591-bib-0026){ref-type="ref"}, [35](#path4591-bib-0035){ref-type="ref"}, [40](#path4591-bib-0040){ref-type="ref"}, [43](#path4591-bib-0043){ref-type="ref"}, [44](#path4591-bib-0044){ref-type="ref"}, [45](#path4591-bib-0045){ref-type="ref"}, [46](#path4591-bib-0046){ref-type="ref"}. IHC showed strong ASPM expression mostly in small, scattered cells with relatively limited cytoplasm, located primarily in the proliferative isthmus zone of rat and human oxyntic mucosa (Figure [2](#path4591-fig-0002){ref-type="fig"}A, B). A similar expression pattern was also found in mouse oxyntic mucosa (Figure [2](#path4591-fig-0002){ref-type="fig"}C) and confirmed by ISH in human mucosa (Figure [2](#path4591-fig-0002){ref-type="fig"}D). The cells were of epithelial origin, as shown by consistent co‐localization with E‐cadherin, and most ASPM‐expressing cells did not seem to be actively dividing, as we could not find compelling co‐localization with Ki67 (or PCNA) (*n =* 250) (Figure [2](#path4591-fig-0002){ref-type="fig"}E, F). Still, morphologically we observed a very few ASPM‐expressing cells (∼0.5%) in division (Figure [2](#path4591-fig-0002){ref-type="fig"}A, E).

![ASPM is expressed in scattered epithelial cells in the oxyntic proliferative isthmus zone. (A--C) Immunostaining showing ASPM expression (brown) in single cells in the isthmus zone (dashed line) of (A) rat oxyntic mucosa (n = 14), (B) human oxyntic mucosa (n = 14) and (C) mouse oxyntic mucosa (n = 4); Lower right inset in (A) shows a rat ASPM‐expressing cell in mitosis. (D) In situ hybridization showing a similar pattern of ASPM mRNA expression in single cells in human oxyntic mucosa (n = 3). (E, F) Double immunofluorescence staining showing co‐expression of ASPM (green) and the epithelial marker E‐cadherin (E‐Cad, red), and no obvious co‐localization of ASPM (green) and the proliferation marker Ki67 (red) in (E) rat oxyntic mucosa (n = 3--10) and (F) human oxyntic mucosa (n = 3--8); insets show an ASPM‐expressing cell (green) in mitosis (rat) and possible co‐localization with PCNA (red) in human. (G, H) Double immunofluorescence staining showing no co‐localization, or limited overlap, as indicated by the arrows, of ASPM (green) and the parietal cell marker H^+^/K^+^‐ATPase (HK, red), ASPM (red) and the mucous neck cell marker GS‐II (green), ASPM (green) and the tuft cell marker DCLK1(red), and ASPM (green) and the neuroendocrine markers synaptophysin (SYN, red) or chromogranin A (CgA, red) in (G) rat oxyntic mucosa (n = 3) and (H) human oxyntic mucosa (n = 3--10). Nuclei were counterstained with DAPI (blue); scale bars = (A, B) 100 µm; (insets) 20 µm; (C--H) 50 µm](PATH-237-447-g002){#path4591-fig-0002}

Established markers were used to determine whether ASPM was expressed by any of the distinct cell types present in the oxyntic isthmus zone. We did not detect co‐localization (each *n =* 100) with H^+^/K^+^‐ATPase (parietal cells) or GS‐II (mucous neck cells) in rat or human, or with DCLK1 (tuft cells [47](#path4591-bib-0047){ref-type="ref"}) in rat (Figure [2](#path4591-fig-0002){ref-type="fig"}G, H). Conversely, a few ASPM‐expressing cells seemed co‐stained for DCLK1 (tuft cells) or chromogranin A (neuroendocrine cells) (both *n =* 2--3/100) in human stomach (Figure [2](#path4591-fig-0002){ref-type="fig"}H) and somewhat more for synaptophysin (neuroendocrine cells) (*n =* 29/100) in rat (Figure [2](#path4591-fig-0002){ref-type="fig"}G). Even though there could be doubts about the explicit localization of synaptophysin, this suggests that some of the ASPM‐expressing cells could have neuroendocrine or tuft cell features. Taken together, our results verify the microarray results at the protein level and show expression of ASPM in single, mainly mature cell marker‐deficient epithelial cells that apparently are not actively dividing and located in the isthmus zone of oxyntic mucosa.

ASPM and E2F1 are over‐expressed in human gastric cancer {#path4591-sec-0013}
--------------------------------------------------------

Given our findings, we investigated further the relevance of ASPM and the possible association with the E2F1 transcription factor in gastric cancer. First, we used western blotting to show that ASPM and E2F1 are indeed expressed in the human gastric adenocarcinoma cell lines AGS, MKN‐45 and KATO‐III; ASPM at high levels in all three cell lines and E2F1 most distinctly in KATO‐III (Figure [3](#path4591-fig-0003){ref-type="fig"}A). Correspondingly, in all cell lines, immunocytochemistry showed ASPM localized to both nuclei and cytoplasm during interphase (Figure [3](#path4591-fig-0003){ref-type="fig"}B) and condensed to the spindle poles in mitotic cells (Figure [3](#path4591-fig-0003){ref-type="fig"}C, D), as previously described [40](#path4591-bib-0040){ref-type="ref"}, [41](#path4591-bib-0041){ref-type="ref"}, [43](#path4591-bib-0043){ref-type="ref"}, [46](#path4591-bib-0046){ref-type="ref"}, [48](#path4591-bib-0048){ref-type="ref"}. E2F1 was mainly observed in the nuclei of non‐mitotic cells, with varying intensity and degree of co‐localization with ASPM (Figure [3](#path4591-fig-0003){ref-type="fig"}B, C). Thus, ASPM and E2F1 are both expressed in gastric adenocarcinoma cells.

![ASPM and E2F1 expression in human gastric cancer cell lines. (A) Representative western blot (n = 4) of ASPM (full‐length) and E2F1 in the gastric cancer cell lines AGS, MKN‐45 and KATO‐III; β‐actin was used as loading control. (B) Immunocytochemical staining of MKN‐45 cells (n = 3), showing cytoplasmic and nuclear localization of ASPM (red; Millipore) and nuclear localization of the transcription factor E2F1 (green) in cells in interphase. (C) Immunocytochemical staining of MKN‐45 cells (n = 3), showing ASPM (green; Bethyl) condensed to the spindle poles in mitotic cells that do not seem to express E2F1 (red). (D) Confocal imaging showing ASPM (green) localized to the spindle poles during metaphase, as indicated by the position of Ki67 (red); nuclear DNA is stained with DAPI (blue). For the confocal image, DAPI, Alexa488 and Alexa647 were excited by 405, 500 and 640 nm laser lines and the fluorescence detected in the ranges 421--475, 510--564 and 653--711 nm, respectively. Sequential imaging was performed to minimize crosstalk. Deconvolution was performed using Huygens Professional software (v 143.06.1p3; Scientific Volume Imaging). Scale bars = (B, C) 25 µm; (D) 5 µm](PATH-237-447-g003){#path4591-fig-0003}

Next, we analysed the mRNA expression profiles of human gastric cancers. Four relevant datasets (346 samples) from Oncomine demonstrated an over‐expression of both *ASPM* and *E2F1* mRNA in gastric cancers compared with non‐tumour gastric tissues, also when distinguishing between different histological subtypes of GAs (149 samples) in datasets from Cho *et al* [49](#path4591-bib-0049){ref-type="ref"} and D\'Errico *et al* [50](#path4591-bib-0050){ref-type="ref"}. This was further supported by our in‐house dataset (Figure [4](#path4591-fig-0004){ref-type="fig"}A, B), which also revealed a significant correlation (*r =* 0.5707, *p \<* 0.0001) between the *ASPM* and *E2F1* expression levels in both non‐tumour tissues and GAs (Figure [4](#path4591-fig-0004){ref-type="fig"}C). To examine this at the protein level, we immunostained a selection of GAs (*n =* 36) and compared the mean index value with that of normal mucosa (*n =* 14) using Fisher\'s exact test. A significant over‐expression (index value \> 3) of ASPM (*p =* 0.0221) and E2F1 (*p =* 0.0044) in tumour cells was found in 11/36 samples (30.6%; Figures [2](#path4591-fig-0002){ref-type="fig"}B, 5A) and 15/36 samples (41.7%; Figure [5](#path4591-fig-0005){ref-type="fig"}A, B), respectively. In normal mucosa, few E2F1‐expressing cells were detected, also mainly in the isthmus zone (Figure [5](#path4591-fig-0005){ref-type="fig"}B). ISH demonstrated that *ASPM* mRNA was present in tumour cells but apparently not in stromal cells, in contrast to the ASPM immunostaining (Figure [5](#path4591-fig-0005){ref-type="fig"}A, C). In our samples we found no correlation between tumours over‐expressing ASPM and E2F1, which might reflect different post‐transcriptional regulation of the transcription factor and the target gene. Still, we observed co‐localization of ASPM and E2F1 in tumour cells (Figure [5](#path4591-fig-0005){ref-type="fig"}D). ASPM and Ki67 on adjacent sections co‐localized to the same areas; however, most of the proliferating cells were not ASPM‐immunoreactive (Figure [5](#path4591-fig-0005){ref-type="fig"}E). Considering the proportion of GAs arising from antral mucosa, the single cell‐expression of ASPM in the isthmus zone was also confirmed in normal antrum (see supplementary material, Figure S2) and the mRNA over‐expression was independent of tumour localization (see supplementary material, Supplementary materials and methods; data not shown). Taken together, our findings show over‐expression of both ASPM and E2F1 in human GAs compared to non‐tumour tissue. A possible association between ASPM and the transcription factor E2F1 was further supported by correlated mRNA levels.

![Expression profile meta‐analysis of ASPM and E2F1 mRNA in human gastric adenocarcinomas, using Oncomine and in‐house datasets. (A) Cho et al [49](#path4591-bib-0049){ref-type="ref"} (ILMN_1815184 Illumina HumanWG‐6 v3.0), D\'Errico et al [50](#path4591-bib-0050){ref-type="ref"} (reporter 232238, Human Genome U133 Plus 2.0 Array) and our in‐house gene expression datasets (ILMN_1815184 Illumina HumanHT‐12) showing increased expression of ASPM mRNA levels in human gastric adenocarcinomas of diffuse, intestinal and mixed type compared with non‐tumour gastric tissues. (B) Cho et al [49](#path4591-bib-0049){ref-type="ref"} (reporter; ILMN_12051469 Illumina Human WG‐6 v. 3.0), D\'Errico et al [50](#path4591-bib-0050){ref-type="ref"} (reporter 204947, Human Genome U133 Plus 2.0 Array) and our in‐house gene expression datasets (ILMN_2051469 Illumina Human HT‐12), showing increased E2F1 mRNA levels in human gastric adenocarcinomas of diffuse, intestinal and mixed type compared to non‐tumour gastric tissues. (C) The mRNA expression levels of ASPM and E2F1 were significantly correlated in the in‐house gene expression dataset; fold changes, symbols, correlation coefficient (r) and p values are as specified in the figure. The Oncomine data show log2 median‐centred intensities, the box plots indicate median and 90% central range, and ![](PATH-237-447-g008.jpg "image") represents maximum and minimum values. The symbols in the in‐house dataset represent individual mRNA expression levels (log2 intensities) in the designated groups, with the blue line indicating median](PATH-237-447-g004){#path4591-fig-0004}

![Immunohistochemical analysis of ASPM and E2F1 protein expression in human gastric adenocarcinomas. (A) Immunostaining showing significantly higher ASPM expression (brown; calculated index value \> 3) compared to normal expression (Figure [2](#path4591-fig-0002){ref-type="fig"}B) in patches of tumour cells with a mainly granular‐like and cytoplasmic pattern (insets with higher magnification). (B) Immunostaining showing significantly higher E2F1 expression (brown; calculated index value \> 3) in nuclei of tumour cells compared to normal expression (calculated index value ≤ 3). (C) In situ hybridization (n = 3) showing a similar pattern of ASPM mRNA expression in tumour cells. (D) Double immunofluorescence staining of adenocarcinomas (n = 2), showing example of co‐expression of ASPM (red) and E2F1 (green) in tumour cells. (E) Immunostaining of adenocarcinomas (n = 3) showing partial co‐localization of ASPM expression (brown) and the proliferation marker Ki67 (brown) in serial sections (![](PATH-237-447-g009.jpg "image")identical positions); scale bars = (A, B, E) 100 µm; (C, D) 50 µm; (insets) 20 µm](PATH-237-447-g005){#path4591-fig-0005}

Discussion {#path4591-sec-0014}
==========

LM is a valuable approach for supporting high‐throughput assays of sub‐samples from complex tissues. In this study, we developed a method for serial section‐navigated LM of the oxyntic proliferative isthmus zone that enabled us to do genome‐wide gene expression analysis without confounding additional amplification. LM has been used previously for genome‐wide analysis of gastric progenitor cells from transgenic parietal cell‐ablated mice (*Atpb4--tox*176) with expansion of the isthmus progenitor cell populations [4](#path4591-bib-0004){ref-type="ref"}, [51](#path4591-bib-0051){ref-type="ref"}. Those reports showed enrichment of GO terms corresponding to those found by us, such as nucleus function, DNA binding/replication, cell cycle/proliferation and translation, but also additional genes involved in growth factor response pathways, mRNA processing and cytoplasmic localization. This could be explained by principal experimental differences, such as the use of transgenic and embryonic mice, three‐way comparisons, whole‐stomach samples and different microarray technology. Our set‐up enabled a more direct analysis of the isthmus, which is generally believed to represent the main stem cell zone for the physiological renewal of gastric oxyntic glands [1](#path4591-bib-0001){ref-type="ref"}, [2](#path4591-bib-0002){ref-type="ref"}, [3](#path4591-bib-0003){ref-type="ref"}, [5](#path4591-bib-0005){ref-type="ref"}, [9](#path4591-bib-0009){ref-type="ref"}. Also, higher‐order analysis showed that different adult tissue stem/progenitor cells share functional properties and patterns of gene expression for internal functions that distinguish them from differentiated cells [52](#path4591-bib-0052){ref-type="ref"}. Our enrichment analysis revealed that the isthmus zone was indeed enriched for genes regulating intracellular processes such as cell cycle and ribosomal activity. Thus, we can deduce that the microdissected isthmus zone contains stem/progenitor cells and that our genome‐wide data can be analysed for features related to stemness.

We showed that genes expressed both at a higher level and uniquely in the isthmus zone compared to the remaining mucosa, are associated with stem cell‐related transcriptional networks and gastric neoplasia. Of particular interest are the unique isthmus zone target genes in the top‐scored E2F1 transcription factor network, which was also top‐scored for the genes associated with stomach neoplasia. The relation of the E2F1 network to both stem cells [26](#path4591-bib-0026){ref-type="ref"}, [27](#path4591-bib-0027){ref-type="ref"} and gastric cancer [53](#path4591-bib-0053){ref-type="ref"}, [54](#path4591-bib-0054){ref-type="ref"}, [55](#path4591-bib-0055){ref-type="ref"}, [56](#path4591-bib-0056){ref-type="ref"} is relatively novel, and the network plays dichotomous roles in controlling counteracting functions, such as cell‐cycle progression versus arrest, apoptosis versus survival and stemness versus differentiation, depending on context [26](#path4591-bib-0026){ref-type="ref"}, [44](#path4591-bib-0044){ref-type="ref"}, [45](#path4591-bib-0045){ref-type="ref"}, [53](#path4591-bib-0053){ref-type="ref"}. One of the genes in the E2F1 network, *Aspm*, was particularly intriguing, being a mitotic spindle pole component and already associated with controlling self‐renewal and symmetrical cell division in neural stem/progenitor cells [35](#path4591-bib-0035){ref-type="ref"}, [36](#path4591-bib-0036){ref-type="ref"}, [37](#path4591-bib-0037){ref-type="ref"}, [38](#path4591-bib-0038){ref-type="ref"}, [40](#path4591-bib-0040){ref-type="ref"}. The expression of ASPM is higher in fetal tissues (including the stomach) [38](#path4591-bib-0038){ref-type="ref"}, [43](#path4591-bib-0043){ref-type="ref"}, [58](#path4591-bib-0058){ref-type="ref"} and it declines markedly during differentiation [35](#path4591-bib-0035){ref-type="ref"}, [36](#path4591-bib-0036){ref-type="ref"}, [38](#path4591-bib-0038){ref-type="ref"}, [41](#path4591-bib-0041){ref-type="ref"}. In the mouse intestine it was found in all epithelial cells during embryonic development but was confined to the stem cell crypts in the adult intestine [39](#path4591-bib-0039){ref-type="ref"}, and it is part of the *Lgr5* intestinal stem cell molecular signature [59](#path4591-bib-0059){ref-type="ref"}. ASPM also regulates Wnt signalling [41](#path4591-bib-0041){ref-type="ref"}, [60](#path4591-bib-0060){ref-type="ref"}, which is probably important in gastric homeostasis [6](#path4591-bib-0006){ref-type="ref"}, [7](#path4591-bib-0007){ref-type="ref"}, [9](#path4591-bib-0009){ref-type="ref"}, [51](#path4591-bib-0051){ref-type="ref"}, [61](#path4591-bib-0061){ref-type="ref"}. The association with E2F1 is relevant, since both seem to be involved in balancing whether stem/progenitor cells proliferate or differentiate [26](#path4591-bib-0026){ref-type="ref"}, [35](#path4591-bib-0035){ref-type="ref"}, [40](#path4591-bib-0040){ref-type="ref"}, [43](#path4591-bib-0043){ref-type="ref"}, [44](#path4591-bib-0044){ref-type="ref"}, [45](#path4591-bib-0045){ref-type="ref"}.

The present study is the first to investigate ASPM in gastric tissues. We identify ASPM as a new interesting cell marker strongly expressed in scattered epithelial cells in the proliferative isthmus zone of oxyntic mucosa and a candidate marker for stem/progenitor cells. The cells are mainly mature cell marker‐deficient, except for a limited overlap with cells with neuroendocrine or tuft cell features. The exact stepwise maturation of these lineages is least established in the oxyntic mucosa [6](#path4591-bib-0006){ref-type="ref"}, [7](#path4591-bib-0007){ref-type="ref"}, [62](#path4591-bib-0062){ref-type="ref"} and ASPM‐expressing cells could represent immature sub‐populations. As ASPM is associated with cell division [35](#path4591-bib-0035){ref-type="ref"}, [36](#path4591-bib-0036){ref-type="ref"}, [40](#path4591-bib-0040){ref-type="ref"}, [41](#path4591-bib-0041){ref-type="ref"}, [43](#path4591-bib-0043){ref-type="ref"}, [48](#path4591-bib-0048){ref-type="ref"}, it was somewhat unexpected not to find clear co‐localization with Ki67, although morphologically the proliferation rate was not zero. Thus, apparently there are either few proliferating ASPM‐expressing cells in oxyntic mucosa or the localization during division makes it difficult to detect. One might speculate that ASPM‐expressing cells could represent quiescent adult stem cells or slow‐cycling progenitor cells for lineages with a long life span, which is a characteristic feature of the oxyntic mucosa [5](#path4591-bib-0005){ref-type="ref"}, [6](#path4591-bib-0006){ref-type="ref"}, [7](#path4591-bib-0007){ref-type="ref"}. Other putative oxyntic stem/progenitor cell markers have also been found intermingled with, but not fully co‐localized to, proliferating cells [5](#path4591-bib-0005){ref-type="ref"}, [63](#path4591-bib-0063){ref-type="ref"}, [64](#path4591-bib-0064){ref-type="ref"}, [65](#path4591-bib-0065){ref-type="ref"}.

ASPM is over‐expressed and correlated with increased malignancy in many human cancers [38](#path4591-bib-0038){ref-type="ref"}, [41](#path4591-bib-0041){ref-type="ref"}, [43](#path4591-bib-0043){ref-type="ref"}, [48](#path4591-bib-0048){ref-type="ref"}, [57](#path4591-bib-0057){ref-type="ref"}, [58](#path4591-bib-0058){ref-type="ref"}, [66](#path4591-bib-0066){ref-type="ref"}. In pancreatic ductal adenocarcinomas, ASPM was recently found negatively associated with glandular differentiation and tubulogenesis, whereas strong expression of ASPM promoted stem cell features and tumour aggressiveness [41](#path4591-bib-0041){ref-type="ref"}. Here, we identify expression of ASPM as relevant for gastric carcinogenesis, showing expression in gastric cancer cell lines and higher levels in GAs. The staining pattern of ASPM in GAs was patchy, similar to the antral stem cell marker LGR5 [11](#path4591-bib-0011){ref-type="ref"}, [23](#path4591-bib-0023){ref-type="ref"}. The partial overlap with proliferating cells could reflect distinct characteristics, fitting with the dynamic and heterogenic nature of the cancer stem cells pool within and between tumours [12](#path4591-bib-0012){ref-type="ref"}, [13](#path4591-bib-0013){ref-type="ref"}. Additionally, aberrant expression of E2F1 is also relevant for gastric cancer, and we are the first to show increased *E2F1* mRNA in GAs by genome‐wide analysis, together with increased E2F1 protein by IHC, as previously reported [53](#path4591-bib-0053){ref-type="ref"}, [54](#path4591-bib-0054){ref-type="ref"}, [55](#path4591-bib-0055){ref-type="ref"}, [56](#path4591-bib-0056){ref-type="ref"}. Our results could imply an association between ASPM and the transcription factor E2F1 in gastric tissue, which is particularly relevant due to their common involvement in crucial cell fate‐regulatory mechanisms. This suggests diverse possible roles for these in tumours, and more functional experiments are needed to further elucidate this association and possible biological relevance.

In summary, we introduce ASPM as a new oxyntic gland cell marker, possibly of stem/progenitor cells, that may be involved in both normal gastric physiology and gastric carcinogenesis. ASPM expression in certain cells could somehow participate in the cellular turnover in the oxyntic mucosa, perhaps by regulating symmetrical versus asymmetrical divisions; thus, ASPM could be an intriguing candidate molecular marker for clonal lineage tracing. Our findings represent a significant contribution to the understanding of the still unidentified oxyntic stem/progenitor cells and their role in tissue homeostasis and cancer.
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**Figure S1.**ADAM17 is mainly expressed in cells of the parietal cell lineage located in the proliferative isthmus zone, confirming the gene expression analysis. Immunostaining for ADAM17 in rat (A) and human (B) oxyntic mucosa shows expression (brown) in parietal cells located throughout the gastric oxyntic glands, with a stronger expression in possible preparietal cells located in the isthmus zone, as indicated by the dashed line. (C) Double immunofluorescence analysis in rat oxyntic mucosa shows an almost complete co‐localization between ADAM17‐expressing cells (green) and cells immunoreactive for the parietal cell marker H^+^/K^+^‐ATPase (red); DAPI‐stained nuclei in blue. Scale bars = 100 µm
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**Figure S2.**ASPM is expressed in scattered single cells in the isthmus zone of rat and human gastric antral mucosa. Immunostaining for ASPM in rat (A) and human (B) antral mucosa show expression (brown) in scattered single cells located in the isthmus zone (dashed line). Scale bars = 100 µm
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**Table S1.**Gene expression analysis, showing genes higher and lower expressed in the microdissected oxyntic proliferative isthmus zone compared to the remaining mucosa
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**Table S2.**Verification of differentially expressed genes in rat oxyntic proliferative isthmus zone compared to the remaining mucosa
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**Table S3.**Genes uniquely expressed in the microdissected oxyntic proliferative isthmus zone
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**Table S4.**Genes higher expressed in the oxyntic proliferative isthmus zone are associated with diseases in the gastrointestinal system
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Click here for additional data file.
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